Since 2011 a 70-year-old Caucasian woman with precedent diagnosis, after a multimodality imaging evaluation, 1 of endomyocardial fi brosis (EMF) was followed for progressive heart failure.
At the diagnosis she presented 4 major diagnostic criteria (endomyocardial plaques, obliteration of the LV apex, LV thrombosis, moderate-to-severe mitral regurgitation) and 2 minor criteria (restrictive fi lling pattern, enlarged left atrium) of EMF. 2 She underwent anuloplasty of the aortic and mitral valves and cardiac resynchronization therapy. After one year the patient's conditions were stable. 1 In the following six years she was admitted more times to our Institute for heart failure (NYHA class III-IV) and showed a progressive increase of brain natriuretic peptide (BNP) ( Fig. 1A) .
Respect to the 2D echocardiography performed after mitral valve surgery ( Fig. 1B ) the apical 4-chamber view, tricuspidal regurgitation and inferior vena cava (IVC) re- 
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Peritoneal dialysis in endomyocardial fi brosis spiratory collapse showed a progressive worsening (Fig.  1C) . Due to the end-stage congestive heart failure peritoneal dialysis was started and just after 6 months patient's conditions (NYHA class IIb -stable decrease in weight of 7 kg), BNP ( Fig. 1A) and 2D echocardiography were improved (Fig. 1D ). EMF is characterized by ventricular hypertrophy and diffuse endocardial thickening due to the deposition of collagen and elastin, with secondary calcifi cation 3 and has a progressive natural history that frequently leads to refractory heart failure.
Nowadays, peritoneal dialysis is a therapeutic alternative in patients with advanced congestive heart failure 4 and represents an alternative therapeutic option in patient not-suitable for cardiac transplantation. 5 In this patient peritoneal dialysis provides, also in the EMF, a safe effective means for dehydrating patients with end-stage congestive heart failure improving patients' cardiac function, symptoms and quality of life.
